|
Ionis Pharmaceuticals, Inc. (Ionen) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Ionis Pharmaceuticals, Inc. (IONS) Bundle
Unabhängig davon, ob Sie ein Investor oder ein Analyst sind, ist dieser DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Ausgestattet mit Ionis Pharmaceuticals, Inc. Reale Daten können Prognosen anpassen und die Auswirkungen in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 729.0 | 810.0 | 587.0 | 787.6 | 705.1 | 718.0 | 731.1 | 744.4 | 757.9 | 771.7 |
| Revenue Growth, % | 0 | 11.11 | -27.53 | 34.18 | -10.48 | 1.82 | 1.82 | 1.82 | 1.82 | 1.82 |
| EBITDA | -107.9 | -.2 | -227.8 | -230.0 | -475.1 | -215.7 | -219.6 | -223.6 | -227.7 | -231.8 |
| EBITDA, % | -14.8 | -0.02950617 | -38.8 | -29.2 | -67.37 | -30.04 | -30.04 | -30.04 | -30.04 | -30.04 |
| Depreciation | 17.2 | 19.6 | 22.1 | 22.5 | .0 | 16.4 | 16.7 | 17.0 | 17.3 | 17.6 |
| Depreciation, % | 2.35 | 2.41 | 3.77 | 2.86 | 0 | 2.28 | 2.28 | 2.28 | 2.28 | 2.28 |
| EBIT | -125.0 | -19.8 | -249.9 | -252.5 | -475.1 | -232.0 | -236.3 | -240.6 | -245.0 | -249.4 |
| EBIT, % | -17.15 | -2.44 | -42.57 | -32.06 | -67.37 | -32.32 | -32.32 | -32.32 | -32.32 | -32.32 |
| Total Cash | 1,892.0 | 2,115.0 | 1,987.0 | 2,331.2 | 2,297.7 | 718.0 | 731.1 | 744.4 | 757.9 | 771.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 76.2 | 61.9 | 25.5 | 97.8 | 92.2 | 68.8 | 70.1 | 71.4 | 72.7 | 74.0 |
| Account Receivables, % | 10.45 | 7.64 | 4.35 | 12.41 | 13.07 | 9.59 | 9.59 | 9.59 | 9.59 | 9.59 |
| Inventories | 22.0 | 24.8 | 22.0 | 28.4 | 12.5 | 21.8 | 22.2 | 22.6 | 23.1 | 23.5 |
| Inventories, % | 3.01 | 3.06 | 3.75 | 3.61 | 1.77 | 3.04 | 3.04 | 3.04 | 3.04 | 3.04 |
| Accounts Payable | 17.2 | 11.9 | 17.9 | 26.0 | 43.0 | 23.4 | 23.8 | 24.2 | 24.7 | 25.1 |
| Accounts Payable, % | 2.36 | 1.47 | 3.05 | 3.3 | 6.09 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 |
| Capital Expenditure | -41.0 | -17.9 | -20.1 | -28.0 | -45.3 | -30.5 | -31.1 | -31.6 | -32.2 | -32.8 |
| Capital Expenditure, % | -5.63 | -2.21 | -3.42 | -3.56 | -6.42 | -4.25 | -4.25 | -4.25 | -4.25 | -4.25 |
| Tax Rate, % | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
| EBITAT | -358.2 | -19.1 | -261.5 | -276.9 | -468.7 | -229.9 | -234.1 | -238.3 | -242.7 | -247.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -463.1 | -11.3 | -214.3 | -353.0 | -475.5 | -249.6 | -249.7 | -254.2 | -258.9 | -263.6 |
| WACC, % | 5.74 | 5.69 | 5.74 | 5.74 | 5.72 | 5.72 | 5.72 | 5.72 | 5.72 | 5.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,081.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -269 | |||||||||
| Terminal Value | -7,220 | |||||||||
| Present Terminal Value | -5,466 | |||||||||
| Enterprise Value | -6,547 | |||||||||
| Net Debt | 1,165 | |||||||||
| Equity Value | -7,713 | |||||||||
| Diluted Shares Outstanding, MM | 150 | |||||||||
| Equity Value Per Share | -51.58 |
What You Will Get
- Real IONS Financial Data: Pre-filled with Ionis Pharmaceuticals’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Ionis Pharmaceuticals’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Accurate Ionis Financials: Gain access to reliable pre-loaded historical data and future projections for Ionis Pharmaceuticals, Inc. (IONS).
- Customizable Forecast Assumptions: Modify highlighted cells such as WACC, growth rates, and profit margins to tailor your analysis.
- Dynamic Calculations: Enjoy automatic updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Visual Dashboard: Utilize clear charts and summaries to effectively visualize your valuation outcomes.
- For Professionals and Beginners: Designed with a user-friendly structure suitable for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-built Excel file featuring Ionis Pharmaceuticals' financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and analyze results immediately.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and industry consultants.
- Accurate Data: Ionis Pharmaceuticals' historical and projected financials preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically calculates intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance to navigate through the calculations.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about trading Ionis Pharmaceuticals stock (IONS).
- Financial Analysts: Enhance valuation accuracy with comprehensive financial models tailored for Ionis Pharmaceuticals.
- Consultants: Provide clients with expert valuation analysis and insights on Ionis Pharmaceuticals efficiently.
- Business Owners: Learn how biotech companies like Ionis Pharmaceuticals are valued to inform your own business strategies.
- Finance Students: Acquire practical valuation skills using real-world data from Ionis Pharmaceuticals.
What the Template Contains
- Pre-Filled Data: Contains Ionis Pharmaceuticals' historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specialized sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Evaluate Ionis Pharmaceuticals' profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth rates, profit margins, and tax assumptions.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.